Amazec Photonics Raises €1.5M To Build Heart Failure Detection

Oudkarspel-based Medtech Amazec Photonics Raises €1.5 million To Develop Morden Heart Failure Detection Technology

Amazec Photonics

Dutch Medtech Amazec Photonics which specialises in photonics medical technology has secured a €1.5 million seed to develop its pioneering minimally invasive diagnosis devices. The round was led by a cross-border growth accelerator and ecosystem of photonic chip technology organization – PhotonDelta, including several private investors. The funds will be used to develop devices for clinical trials.

It should be borne in mind that cardiovascular diseases are the world’s leading cause of death accounting for 19 million deaths a year based on statistics. This is a result of the difficulty in diagnosing conditions that lead to delays in treatment. To curb this, the subject med-tech’s solution has become a huge step forward in this battle, noting that it can enable much earlier and much more accurate diagnosis for minimal costs and complexity.

“The number of people suffering from cardiovascular diseases has risen by 93% over the past 25 years and now impacts an estimated 550 million patients worldwide. Many of these people will die or suffer poor health outcomes because the tools we have to diagnose them simply aren’t good enough. Our solution can make a real difference because, not only does it vastly improve the accuracy of testing for cardiovascular disease, it is also much less invasive and simpler to use. This will substantially reduce costs and open the door to many more people being tested much more regularly. With this funding round we will be able to build ten prototypes and undertake extensive clinical trials with the intention of producing and selling devices across the EU by 2028”, ‘Pim Kat’, CEO of Amazec Photonics, said.

Founded in 2021, the subject company creates easy-to-apply cardiovascular monitoring tools. While existing solutions are proven to be complex, invasive, and often inaccurate. Currently, the most often deployed technique to measure cardiac output is known as thermodilution which is carried out by injecting a known volume of liquid upstream of the heart and then measuring temperature changes downstream through specialized catheters inserted into the patient. However, this approach has several drawbacks including the inability to be used reliably during routine examination, large variation between measurements, a lack of sensitivity, and high costs. Consequently, the subject measure often leads to late or misdiagnosis – severely impacting the outlook for patients.

Amazec’s solution, in contrast, uses photonics-based tech to measure temperature changes to an unprecedented precision of 0.0001 degree Celsius (compared to currently in use with an accuracy of 0.01 degree Celsius). Furthermore, the monitoring device is deployed externally, which means it’s needless to insert catheters. In addition to its efficacy, multiple measurements can be made in real-time, thereby improving reliability – this is in contrast to the single measurement currently deployed in the field of medical practice.

“Amazec has leveraged the power of photonics to create a device that can make a profound impact on the world. Cardiovascular disease is one of the biggest health challenges we face and better diagnosis can be the key to saving millions of lives. We’re very proud to be a part of Amezec’s journey – we believe it has the capacity to become one of Europe’s most important medtechs and a standard bearer for a new generation of photonics-based technology”, ‘Laurens Weers’, CFO of PhotonDelta, added.

PhotonDelta’s investment in Amazec Photonics is known to be the latest step in the organization’s goal of creating a world-leading photonics industry in the Netherlands. It’s also worth noting that PhotonDelta plans to help build 200 startups, create new applications for photonic chips, and develop infrastructure and talents.

The subject company (Amazec) will at this juncture begin clinical trials of its device at Catharina Hospital in Eindhoven this year, with an expansion to three other hospitals planned in 2025, aimed at starting full-scale production and sale across the EU markets in 2028.